HCPLive Five at AAD 2024

Описание: Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This first edition shares 5 important updates from the American Academy of Dermatology (AAD) 2024 meeting.

The sunny locale of San Diego, California was the perfect location to inspire dermatologists from all corners of the country to converge and discuss the major trends in the field. On-site at AAD 2024, the HCPLive editorial team had the opportunity to interview several key opinion leaders on their teams’ late-breaking data, new treatment developments, and the seemingly daily changes in the field.

Here are 5 of our top stories from AAD 2024:

Joel Gelfand, MD, MSCE describes the feasibility and efficacy of at-home phototherapy for patients with psoriasis.
https://www.hcplive.com/view/joel-gel...

Andrew Blauvelt, MD, MBA explains how a high-dose, brief regimen of risankizumab was associated with significantly reduced psoriasis in patients after 1 year.
https://www.hcplive.com/view/rizankiz...

Andrew F. Alexis, MD, MPH, reports interim data from the open-label ADmirable phase 3b study on the efficacy of lebrikizumab in patients with skin of color and moderate-to-severe atopic dermatitis.
https://www.hcplive.com/view/andrew-a...

Alexa Kimball, MD, MPH unravels late-breaking data on the safety and efficacy of lutikizumab in treating moderate-to-severe hidradenitis suppurativa (HS) among adult non-responders to anti-TNF therapy.
https://www.hcplive.com/view/discussi...

James Q. Del Rosso, DO, shares his perspective on the recent news on a potential beneze risk in common acne treatment ingredient benzoyl peroxide.
https://www.hcplive.com/view/benzoyl-...

#dermatology #AAD2024